Welcome to our dedicated page for Organogenesis Hldgs news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Hldgs stock.
Organogenesis Holdings Inc. (Nasdaq: ORGO) is a regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. The Organogenesis news feed highlights company announcements, clinical updates, financial results, and regulatory developments that help investors and healthcare professionals understand how the business is evolving.
News about Organogenesis frequently covers its regenerative medicine portfolio and its position in the skin substitutes and cellular and tissue-based products (CTP) market. The company issues press releases on quarterly and year-to-date financial performance, including net product revenue from Advanced Wound Care and Surgical & Sports Medicine products, net income or loss, and adjusted metrics such as adjusted net income and adjusted EBITDA. These updates often include management commentary on market conditions, reimbursement dynamics, and expectations for future periods.
A major theme in Organogenesis news is the development of ReNu, a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis. The company publishes detailed updates on Phase 3 randomized controlled trials, including pain and function outcomes, safety observations, and plans for regulatory submissions. Announcements have described FDA Regenerative Medicine Advanced Therapy (RMAT) designation for ReNu, plans for a Biologics License Application (BLA), and the initiation of a rolling BLA submission.
Additional news items include commentary on Centers for Medicare & Medicaid Services (CMS) payment reforms for skin substitutes/CTPs, participation in investor conferences, and corporate governance developments such as inducement equity grants and stockholder meeting results. By following this page, readers can review a chronological record of how Organogenesis communicates its financial performance, clinical progress, reimbursement environment, and corporate actions.
Organogenesis Holdings (Nasdaq: ORGO) announces participation as a Platinum Sponsor at the 2020 Symposium on Advanced Wound Care (SAWC) Virtual Experience from July 24-26. The company's advanced wound care research, including products like Apligraf and Dermagraft, will be showcased. Highlights include an Innovation Theater event and multiple virtual Private Networking Suites for attendees to engage with experts. Key poster presentations cover studies on various wound treatments, including living cellular constructs and collagen dressings for venous leg ulcers.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has scheduled its second quarter 2020 financial results announcement for August 10, 2020, after market close. A conference call will follow at 5:00 p.m. ET, providing updates and a question and answer session. Investors can join by dialing 866-795-3142 or via a live webcast on the company’s investor relations website. A replay will be available for two weeks. Organogenesis specializes in regenerative medicine products for Advanced Wound Care and Surgical markets.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported net revenue of $61.7 million for Q1 2020, an increase of 8% from $57.1 million in Q1 2019. Advanced Wound Care products generated $51.3 million, up 7%, while Surgical & Sports Medicine products increased 13% to $10.4 million. Despite revenue growth, the company recorded a net loss of $16.3 million, compared to a $15.7 million loss a year earlier. The company withdrew its fiscal year 2020 revenue guidance due to uncertainty from the COVID-19 pandemic, prioritizing cost-saving measures.